US 12,472,167 B2
Methods providing a therapeutic macromolecule and synthetic nanocarriers comprising immunosuppressant locally and concomitantly to reduce both Type 1 and Type IV hypersensitivity
Roberto A. Maldonado, Berkeley, CA (US)
Assigned to Cartesian Therapeutics, Inc., Frederick, MD (US)
Filed by Cartesian Therapeutics Inc., Gaithersburg, MD (US)
Filed on Mar. 9, 2022, as Appl. No. 17/690,437.
Application 17/690,437 is a continuation of application No. 16/438,147, filed on Jun. 11, 2019, granted, now 11,298,342.
Application 16/438,147 is a continuation of application No. 14/269,054, filed on May 2, 2014, granted, now 10,357,482.
Claims priority of provisional application 61/948,384, filed on Mar. 5, 2014.
Claims priority of provisional application 61/948,313, filed on Mar. 5, 2014.
Claims priority of provisional application 61/907,177, filed on Nov. 21, 2013.
Claims priority of provisional application 61/881,851, filed on Sep. 24, 2013.
Claims priority of provisional application 61/881,913, filed on Sep. 24, 2013.
Claims priority of provisional application 61/881,921, filed on Sep. 24, 2013.
Claims priority of provisional application 61/819,517, filed on May 3, 2013.
Prior Publication US 2023/0032226 A1, Feb. 2, 2023
This patent is subject to a terminal disclaimer.
Int. Cl. A61K 39/395 (2006.01); A61K 9/00 (2006.01); A61K 9/127 (2006.01); A61K 9/51 (2006.01); A61K 31/192 (2006.01); A61K 31/436 (2006.01); A61K 38/19 (2006.01); A61K 38/21 (2006.01); A61K 38/37 (2006.01); A61K 38/43 (2006.01); A61K 38/47 (2006.01); A61K 45/06 (2006.01); A61K 47/69 (2017.01); C07K 16/18 (2006.01); C07K 16/24 (2006.01); C07K 16/40 (2006.01); A61K 39/00 (2006.01)
CPC A61K 31/436 (2013.01) [A61K 9/0019 (2013.01); A61K 9/127 (2013.01); A61K 9/5115 (2013.01); A61K 9/5153 (2013.01); A61K 9/5192 (2013.01); A61K 31/192 (2013.01); A61K 38/19 (2013.01); A61K 38/21 (2013.01); A61K 38/37 (2013.01); A61K 38/43 (2013.01); A61K 38/47 (2013.01); A61K 39/39533 (2013.01); A61K 39/3955 (2013.01); A61K 45/06 (2013.01); A61K 47/6923 (2017.08); A61K 47/6929 (2017.08); A61K 47/6935 (2017.08); A61K 47/6937 (2017.08); C07K 16/18 (2013.01); C07K 16/241 (2013.01); C07K 16/40 (2013.01); A61K 2039/505 (2013.01); C12Y 305/01001 (2013.01)] 20 Claims
 
1. A method comprising:
providing a therapeutic dose of a therapeutic macromolecule, wherein the therapeutic macromolecule is not attached to synthetic nanocarriers;
providing a composition comprising synthetic nanocarriers that are attached to immunosuppressants; and
administering the composition and the therapeutic dose of the therapeutic macromolecule to a subject concomitantly,
and
wherein the concomitant administration of the composition and the therapeutic dose of the therapeutic macromolecule reduces both Type 1 hypersensitivity and Type IV hypersensitivity in the subject.